Herantis Pharma Oyj Share Price

Equities

HRTIS

FI4000087861

Biotechnology & Medical Research

Delayed Nasdaq Helsinki 05:04:01 30/04/2024 pm IST 5-day change 1st Jan Change
1.4 EUR -1.41% Intraday chart for Herantis Pharma Oyj -3.45% -11.11%

Financials

Sales 2024 * 1.3M 1.39M 116M Sales 2025 * - Capitalization 28.23M 30.13M 2.51B
Net income 2024 * -3M -3.2M -267M Net income 2025 * -4M -4.27M -356M EV / Sales 2024 * 18.5 x
Net cash position 2024 * 4.2M 4.48M 374M Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 10
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.93%
More Fundamentals * Assessed data
Dynamic Chart
Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024
Transcript : Herantis Pharma Oyj - Special Call
Herantis Pharma's Early-stage Study of Parkinson's Therapy Shows Positive Data; Stock Surges MT
Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096 CI
Herantis Pharma Secures EUR4.5 Million Loan Waive-off From Business Finland MT
Transcript : Herantis Pharma Oyj, H1 2023 Earnings Call, Aug 24, 2023
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study CI
Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096 CI
Herantis Pharma Doses First Patient in Phase 1 Trial for Parkinson's Disease Therapy MT
Herantis Pharma Oyj Announces First Healthy Volunteer Dosed in the Phase 1a Clinical Study for the Parkinson's Disease Drug Candidate, HER-096 CI
Transcript : Herantis Pharma Oyj, H2 2022 Earnings Call, Mar 02, 2023
Herantis Pharma Shares Surge on Approval of Clinical Trial Application For Parkison's Disease Treatment MT
Herantis Pharma plc Announces Approval of Clinical Trial Application for A Phase 1 Study for HER-096 CI
More news
1 day-1.41%
1 week-3.45%
Current month-0.36%
1 month-0.36%
3 months-5.41%
6 months-16.67%
Current year-11.11%
More quotes
1 week
1.40
Extreme 1.4
1.50
1 month
1.40
Extreme 1.4
1.53
Current year
1.17
Extreme 1.17
1.60
1 year
1.17
Extreme 1.17
2.20
3 years
1.17
Extreme 1.17
3.59
5 years
1.17
Extreme 1.17
10.80
10 years
0.77
Extreme 0.765
11.00
More quotes
Managers TitleAgeSince
Founder - 01/08/01
Chief Executive Officer - 12/18/12
Director of Finance/CFO 55 26/20/26
Members of the board TitleAgeSince
Director/Board Member 53 01/14/01
Director/Board Member 53 11/20/11
Chairman 64 01/12/01
More insiders
Date Price Change Volume
30/24/30 1.4 -1.41% 5,376
29/24/29 1.42 -2.74% 17,868
26/24/26 1.46 +2.10% 9,116
25/24/25 1.43 -4.35% 14,381
24/24/24 1.495 +1.36% 37,018

Delayed Quote Nasdaq Helsinki, April 30, 2024 at 05:04 pm IST

More quotes
Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.
Calendar
More about the company

Annual profits - Rate of surprise